Gilead signs $425m cooperation agreement with Precision BioSciences (Hepatitis B)

Gilead Sciences, Precision BioSciences have jointly announced it a strategic cooperation agreement aimed at developing new therapies targeting the in vivo elimination of hepatitis B virus (HBV) with Precision’s proprietary genome editing platform, Arcus. As part of the agreement, Precision will be responsible for the development, formulation, and preclinical evaluation of therapies, while Gilead will be responsible for the clinical development and commercialization of them and will fund the whole research. Additionally, Precision will be paid $445m, subject to fulfillment of precise technical milestones; in addition, it will receive royalties if the products are finally marketed.

(Source: Gilead)